Skip to main content
Clinical Trials/NCT01530295
NCT01530295
Unknown
Not Applicable

Biochemical Recurrence Rate of Radical Prostatectomy Combined With Neoadjuvant and Adjuvant in Patients With High Risk Locallized Prostate Cancer

Hanjong Ahn1 site in 1 country70 target enrollmentJuly 2008
ConditionsProstate Cancer
InterventionsDOCETAXEL

Overview

Phase
Not Applicable
Intervention
DOCETAXEL
Conditions
Prostate Cancer
Sponsor
Hanjong Ahn
Enrollment
70
Locations
1
Primary Endpoint
biochemical recurrence rate of Radical Prostatectomy Combined with Neoadjuvant and Adjuvant Chemotherapy in Patients with High Risk Prostate Cancer
Last Updated
14 years ago

Overview

Brief Summary

Effect of Radical Prostatectomy Combined with Neoadjuvant and Adjuvant Chemotherapy in Patients with High Risk Prostate Cancer.

The purpose of this study is to evaluate whether neoajuvant and adjuvant docetaxel and prednisone are effective in the treatment of high risk localized prostate cancer.

Detailed Description

The purpose of this study is to evaluate whether neoajuvant and adjuvant docetaxel and prednisone are effective in the treatment of high risk localized prostate cancer.

Registry
clinicaltrials.gov
Start Date
July 2008
End Date
July 2012
Last Updated
14 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Male

Investigators

Sponsor
Hanjong Ahn
Responsible Party
Sponsor Investigator
Principal Investigator

Hanjong Ahn

Professor

Asan Medical Center

Eligibility Criteria

Inclusion Criteria

  • Prostate Cancer
  • PSA \> 20 OR
  • Clinical Stage \> T2C OR

Exclusion Criteria

  • Not provided

Arms & Interventions

contol

control group

Intervention: DOCETAXEL

chemotherapy

neoadjuvant chemotherapy

Intervention: DOCETAXEL

Outcomes

Primary Outcomes

biochemical recurrence rate of Radical Prostatectomy Combined with Neoadjuvant and Adjuvant Chemotherapy in Patients with High Risk Prostate Cancer

Time Frame: 2 Years After RRP

Study Sites (1)

Loading locations...

Similar Trials